{"id":134085,"date":"2026-07-23T12:24:36","date_gmt":"2026-07-23T12:24:36","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/134085\/"},"modified":"2026-07-23T12:24:36","modified_gmt":"2026-07-23T12:24:36","slug":"watch-out-eli-lilly-and-novo-nordisk-viking-therapeutics-just-started-testing-a-weight-loss-drug-that-goes-beyond-glp-1-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/134085\/","title":{"rendered":"Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The human appetite has more than one off switch, and drugmakers like Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are doing their darndest to identify and develop a medicine to target every single one.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">On June 24, Viking Therapeutics (NASDAQ: VKTX) announced a phase 1 trial for one of its candidates that&#8217;s attempting to flip one of those as-yet unmedicated appetite switches. That marks its first obesity candidate working outside the incretin pathway that includes GLP-1, or glucagon-like peptide-1, the hormone behind Ozempic and Wegovy and one of two hormones behind Zepbound and Mounjaro.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Missed Nvidia in 2009? This Rare Signal Is Flashing Again.\u00a0In 2009, a &#8220;Double Down&#8221; signal flashed for a little-known chipmaker called Nvidia.\u00a0For the first time in years, that same &#8220;Total Conviction&#8221; signal is flashing for a company 1\/100th the size of Nvidia.\u00a0<a href=\"https:\/\/api.fool.com\/infotron\/infotrack\/click?apikey=35527423-a535-4519-a07f-20014582e03e&amp;impression=a9c97f23-d287-417b-8e68-4e465693308c&amp;url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fa-sa-dd-total-conviction%3Faid%3D11123%26source%3Disaediica0000074%26ftm_cam%3Dsa-dd-4%26ftm_veh%3Dtop_incontent_pitch_feed_yahoo%26ftm_pit%3D19375&amp;utm_source=yahoo-host-full&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=c2afdd82-3964-44ad-ae42-a3ca92b03a4f\" data-ylk=\"slk:Continue%20%C2%BB;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Continue \u00bb&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Continue \u00bb<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Let&#8217;s take a look at this program and determine whether it&#8217;s really going to be a threat to Novo Nordisk and Eli Lilly.  <\/p>\n<p>    <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/2D001D025867DAB7BA5054CFC8453CD0C61574BC3240892F9034B5D03AC6E0AB\/subgraphmysterio\/resizefit_w960;quality_80;format_webp\/https:%2F%2Fmedia.zenfs.com%2Fen%2Fmotleyfool.com%2F2a44695d192baf4ef63baf5ce2cd5a6f\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Two scientists stand in a laboratory, discussing data on a tablet.\" height=\"640\" width=\"960\" class=\"yf-lf2kr7 loader\"\/><\/a> Image source: Getty Images.           This hormone is already a hot target          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Amylin is a hormone produced in the pancreas that is released with insulin after a meal, activating receptors in the brain stem that promote the feeling of fullness, and also slowing stomach emptying. That pathway is adjacent to the one that the <a href=\"https:\/\/www.fool.com\/investing\/how-to-invest\/stocks\/glp-1-stocks\/?utm_source=yahoo-host-full&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=c2afdd82-3964-44ad-ae42-a3ca92b03a4f\" data-ylk=\"slk:GLP-1%20medicines;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;GLP-1 medicines&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">GLP-1 medicines<\/a> use, so it could technically be targeted by a combination therapy affecting both.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">VK3019, Viking&#8217;s new candidate, is a dual amylin and calcitonin receptor agonist. Additionally targeting calcitonin activation is meant to yield metabolic effects amylin alone does not; preclinical animal model data showed that the combination led to up to 8% weight reduction against controls.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The new phase 1 trial, announced on June 24, is being conducted in adults with a body mass index of 30 or above, and the candidate is formulated as an injection. If Viking&#8217;s dual targets work as desired, the company could be on the way to producing a leading next-generation weight loss candidate &#8212; but <a href=\"https:\/\/www.fool.com\/investing\/stock-market\/market-sectors\/healthcare\/pharmaceutical-stocks\/?utm_source=yahoo-host-full&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=c2afdd82-3964-44ad-ae42-a3ca92b03a4f\" data-ylk=\"slk:its%20bigger%20competitors;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;its bigger competitors&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">its bigger competitors<\/a> are way ahead of it.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Eli Lilly reported phase 2 results for eloralintide, an amylin receptor agonist, in November 2025; across dosing arms, patients experienced mean weight reductions of 9.5% to 20.1% after 48 weeks, against a loss of 0.4% with placebo. Phase 3 is already in progress.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo Nordisk has gone even further. Its candidate cagrilintide produced 11.8% weight loss against 2.3% for placebo over a 68-week period; its phase 3 program began in late 2025. A combination drug program called CagriSema, which contains cagrilintide plus semaglutide (the active ingredient of Ozempic and Wegovy), was submitted to the U.S. Food and Drug Administration (FDA) in December, with review expected this year.  <\/p>\n<p>            The combination approach is popular, too         <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">So Viking Therapeutics won&#8217;t be the first to market with its amylin program, even if its clinical trials go swimmingly.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">But Viking already owns VK2735, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors that&#8217;s in phase 3 trials. Pairing it with an amylin candidate like VK3019 could deliver the results that would keep the company relevant in the next round of the competition in weight loss drugs. And, as a pre-revenue biotech, it wouldn&#8217;t even need to win that much of the market for its shares to see meaningful gains.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The catch is that Lilly is already running that exact play. A phase 1 study of eloralintide administered with tirzepatide (Mounjaro, Zepbound) has completed, and a phase 3 trial adding eloralintide to a weekly incretin is enrolling now. Viking is thus trying to assemble what both incumbents built years ago.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">That means VK3019 is going to need to be substantially more effective or more pleasant to take if the biotech is going to secure a large share of the market. It&#8217;s certainly possible &#8212; but it&#8217;s very risky to bet on it.  <\/p>\n<p>          Should you buy stock in Viking Therapeutics right now?         <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Before you buy stock in Viking Therapeutics, consider this:  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The Motley Fool Stock Advisor analyst team just identified what they believe are the\u00a0<a href=\"https:\/\/api.fool.com\/infotron\/infotrack\/click?apikey=35527423-a535-4519-a07f-20014582e03e&amp;impression=2a307988-b656-4745-b5b9-bb1ce0621129&amp;url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fe-sa-bbn-bn%3Faid%3D8867%26source%3Disaeditxt0001181%26ftm_cam%3Dsa-bbn-evergreen%26ftm_veh%3Darticle_pitch_feed_yahoo%26ftm_pit%3D18781&amp;utm_source=yahoo-host-full&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=c2afdd82-3964-44ad-ae42-a3ca92b03a4f\" data-ylk=\"slk:10%20best%20stocks;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;10 best stocks&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">10 best stocks<\/a> for investors to buy now\u2026 and Viking Therapeutics wasn&#8217;t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Consider when Netflix made this list on December 17, 2004&#8230; if you invested $1,000 at the time of our recommendation,\u00a0you&#8217;d have $371,842!* Or when Nvidia made this list on April 15, 2005&#8230; if you invested $1,000 at the time of our recommendation, you&#8217;d have $1,244,783!*  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Now, it&#8217;s worth noting\u00a0Stock Advisor&#8217;s total average return is 900% \u2014 a market-crushing outperformance compared to 207% for the S&amp;P 500.\u00a0Don&#8217;t miss the latest top 10 list, available with\u00a0Stock Advisor, and join an investing community built by individual investors for individual investors.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/api.fool.com\/infotron\/infotrack\/click?apikey=35527423-a535-4519-a07f-20014582e03e&amp;impression=2a307988-b656-4745-b5b9-bb1ce0621129&amp;url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fe-sa-bbn-bn%3Faid%3D8867%26source%3Disaeditxt0001181%26ftm_cam%3Dsa-bbn-evergreen%26ftm_pit%3D18781%26ftm_veh%3Darticle_pitch_feed_yahoo%26company%3DViking%2520Therapeutics&amp;utm_source=yahoo-host-full&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=c2afdd82-3964-44ad-ae42-a3ca92b03a4f\" data-ylk=\"slk:See%20the%2010%20stocks%20%C2%BB;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;See the 10 stocks \u00bb&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" class=\"ticker_pitch\">See the 10 stocks \u00bb<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">*Stock Advisor returns as of July 18, 2026.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.fool.com\/author\/20287\/\" data-ylk=\"slk:Alex%20Carchidi;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Alex Carchidi&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Alex Carchidi<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a <a href=\"https:\/\/www.fool.com\/legal\/fool-disclosure-policy\/\" data-ylk=\"slk:disclosure%20policy;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;disclosure policy&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">disclosure policy<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.fool.com\/investing\/2026\/07\/18\/watch-out-eli-lilly-and-novo-nordisk-viking-just\/\" data-ylk=\"slk:Watch%20Out%2C%20Eli%20Lilly%20and%20Novo%20Nordisk%3A%20Viking%20Therapeutics%20Just%20Started%20Testing%20a%20Weight%20Loss%20Drug%20That%20Goes%20Beyond%20GLP-1;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1<\/a> was originally published by The Motley Fool  <\/p>\n","protected":false},"excerpt":{"rendered":"The human appetite has more than one off switch, and drugmakers like Eli Lilly (NYSE: LLY) and Novo&hellip;\n","protected":false},"author":2,"featured_media":134086,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[65092,276,272,278,51985,618,9746,12795],"class_list":["post-134085","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-candidate","tag-eli-lilly","tag-novo-nordisk","tag-nyse","tag-receptor-agonist","tag-viking","tag-viking-therapeutics","tag-weight-reduction"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116969279747211838","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/134085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=134085"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/134085\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/134086"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=134085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=134085"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=134085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}